Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mr. Pink's Picks: selected event-driven value investments -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Pink who wrote (1214)	3/16/1998 10:19:00 AM
From: Nicholas P. Acquaviva Jr.	Read Replies (1) \| Respond to of 18998

Mr. Pink, I like one of the announcements made by DOSE today but the other biz.yahoo.com makes me think DILUTION! What say Thee? All the best! Nick

To: Mr. Pink who wrote (1214)	3/16/1998 12:33:00 PM
From: George Kirlin	Respond to of 18998

Mr. Pink, Sorry never owned CLCX...So, prove to me you're short CCSI?

To: Mr. Pink who wrote (1214)	3/16/1998 1:38:00 PM
From: Goulds	Respond to of 18998

hey pink... how about your strong buy for AHG. Now that it's sinking so fast, should we buy more and average down? HJave you shorted it yet? When's it going to do it's predicted turnaround and make all the suckers that fell for your advice some of the "real money"... same time ACRT goes down to zero I suppose...

To: Mr. Pink who wrote (1214)	3/16/1998 2:38:00 PM
From: Gurupup	Read Replies (1) \| Respond to of 18998

Monday March 16, 1:45 pm Eastern Time Hey Pinky, whatcha think???????? Company Press Release CCSI Announces Launch of New Medical Product at International Medical Conference May 1, 1998 NEW YORK--(BUSINESS WIRE)--March 16, 1998--Chromatics Color Sciences, International Inc. (NASDAQ:CCSID - news) announced today that it will be introducing both its new hand-held device and new console model of the device for the non-invasive detection and monitoring of bilirubin infant jaundice at the 1998 Pediatric Academic Societies' Annual International Exposition in New Orleans May 1-5, 1998. This is the largest Pediatric Research Conference held. The introduction to the international pediatric and neonatal medical community will be in the New Products section of the conference, featuring only those products newly given FDA clearances for commercial marketing. Dr. Ian Holzman, Chief of Newborn Medicine, Mt. Sinai Hospital, NYC will be presenting to the conference his medical papers on the positive results of the device in extensive clinical trials conducted on infants of all races and those under phototherapy treatment at Mt. Sinai Hospital and Elmhurst Hospital in New York City. The initial results of multi-site clinical studies of the device for the same indications, the first of which commenced under Dr. Jeffrey Maisels, Chairman, Dept. of Pediatrics at William Beaumont Hospital in Detroit will be presented at a reception for the introduction of the new product to pediatricians and neonatologists. The company is currently finalizing its mass-manufacturing production schedule under FDA QSR and GMP as well as ISO 9000 manufacturing regulatory requirements for both the console model and the light weight (360 gms.) hand-held battery operated device, each of which includes a proprietary calibration disposable for each non-invasive measurement taken on an infant while being monitored for hyperbilirubinemia. The company has received a letter from the American Medical Association permitting 3rd party insurance reimbursement in all U.S. states for each use of the company's non-invasive device under AMA Code CPT 82250, which is the same reimbursement code for the laboratory blood test currently used to monitor hyperbilirubinemia. The company has been in ongoing discussions with potential partners for international medical distribution of its new product and is currently conducting negotiations to reach definitive agreements. The company is engaged in the business of color science and has developed technologies with medical applications involving the detection and monitoring of certain chromogenic diseases. These technologies also have other applications including the scientific color measurement and classification of human skin, certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty aid and fashion industries. The company's common stock is traded on NASDAQ under the symbol ''CCSID''. Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business which may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, the availability of any needed financing, the company's ability to implement its long range business plan for various applications for its technologies, the impact of competition, the obtaining of further regulatory clearances applicable to proposed new applications of the company's technology, management

To: Mr. Pink who wrote (1214)	3/17/1998 1:27:00 AM
From: iceman100	Respond to of 18998

As i found this thread I had to wonder how anyone could blindly follow someone with the name of MR pink. You traders must be very rich or very stoned-maybe both. CCSI is going to crush(not squeeze) you soon. With a contract of only $15mil that is a pe of 15. Not very high for the drug sector. What will happen to you when the contract is annouced at 20to 30 mil. It's all over for you and mr pink. FACT- the negotiations are going on now. FACT- they have FDA approval. Favor -don't cover on the open- I'm Buying more. MR pink- what a joke. Save your money traders